Cabozantinib-d4 (S-malate)

Cabozantinib-d4 (S-malate) (XL184-d4 (S-malate) ; BMS-907351-d4 (S-malate) ) is the deuterium labeled Cabozantinib (S-malate) (HY-12044) . Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

Product Specifications

Product Name Alternative

XL184-d4 (S-malate) ; BMS-907351-d4 (S-malate)

UNSPSC

12352005

Target

Apoptosis; Isotope-Labeled Compounds; VEGFR

Related Pathways

Apoptosis; Others; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Smiles

O=C(NC(C([2H])=C1[2H])=C(C([2H])=C1OC2=CC=NC3=C2C=C(C(OC)=C3)OC)[2H])C4(C(NC5=CC=C(C=C5)F)=O)CC4.O[C@@H](CC(O)=O)C(O)=O

Molecular Formula

C32H26D4FN3O10

Molecular Weight

639.62

References & Citations

[1]Torres KE, et al. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res, 2011, 17 (12), 3943-3955.|[2]You WK, et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res, 2011, 71 (14), 4758-4768.|[3]Yakes FM, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther, 2011, 10 (12), 2298-2308.